Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference
November 05 2021 - 7:01AM
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical
company engaged in the commercialization and development of
innovative anti-infective agents to treat serious infections, today
announced that Ted Schroeder, Chief Executive Officer at Nabriva,
will provide a company overview and business update at the
Jefferies London Healthcare Conference. The presentation will be
available on-demand beginning on Thursday, November 18 at 8:00am
GMT / 3:00am ET through Friday, November 19 at 5:00pm GMT / 12:00pm
ET. Management will host investor meetings on Thursday and Friday,
November 18-19, 2021.
The presentation may be accessed by visiting the
"Investors" section of the Company's website under the "Events and
Presentations" tab at www.nabriva.com. A replay of the webcast will
be available for 90 days.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in
the commercialization and development of innovative anti-infective
agents to treat serious infections. Nabriva Therapeutics received
U.S. Food and Drug Administration approval for XENLETA® (lefamulin
injection, lefamulin tablets), the first systemic pleuromutilin
antibiotic for community-acquired bacterial pneumonia (CABP).
Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for
injection, a potential first-in-class epoxide antibiotic for
complicated urinary tract infections (cUTI), including acute
pyelonephritis. Nabriva entered into an exclusive agreement with
subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to
market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the
United States and certain of its territories.
CONTACTS:
For InvestorsKim AndersonNabriva Therapeutics
plcir@nabriva.com
For MediaAndrea
GreifOgilvyandrea.greif@ogilvy.com914-772-3027
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Sep 2023 to Sep 2024